Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at Oncolytic Virotherapy Summit 2023 on December 13

2023-12-11

临床研究

PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc. (STI), announced today that Dr. Paul Hallenbeck will present a talk at the 8th Oncolytic Virotherapy Summit 2023 entitled “Assessing the Benefits and Challenges of Intravenous Delivery of Oncolytic Viruses”. In his talk, Dr. Hallenbeck will discuss the challenges inherent in doing multiple (IV) intravenous administrations of oncolytic viruses, where the field is meeting these challenges, and present data on the development of multiple IV technology for STI’s oncolytic virus SVV-001, a clinical stage oncology product.

'There are several important hurdles to be overcome to develop the capability of performing multiple intravenous delivery of an oncolytic virus'

“There are several important hurdles to be overcome to develop the capability of performing multiple intravenous delivery of an oncolytic virus,” said Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics. “These include cost of goods, high cancer target selectivity, elimination and/or avoidance of existing neutralizing antibodies and obtaining significant replication at the tumor site. SVV-001 has the profile to potentially meet all these multiple challenges.”

About Seneca Therapeutics

Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.

www.senecatherapeutics.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构